Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman

SAN FRANCISCO, Nov. 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-Founder and Chief Executive Officer (CEO) Matthew R. Patterson has been appointed Chairman of the Board of Directors.  The Board of Directors also appointed Louis G. Lange, M.D., Ph.D. as Lead Independent Director.  Mr. Patterson and Dr. Lange have held board member roles since 2012 and 2015, respectively.  

"It is a great privilege for me to serve our company as Chairman of the Board of Directors," stated Matthew R. Patterson, Chairman and CEO.  "Audentes is at an exciting inflection point, and I look forward to working closely with the board and management team to deliver on important milestones that advance our mission of developing innovative gene therapy products for patients living with serious, life-threatening rare diseases."

Mr. Patterson continued, "I am also pleased to announce the appointment of Dr. Lange to the position of Lead Independent Director.  Lou is a recognized leader in the biotechnology industry who brings a unique and valued perspective to our organization.  We're fortunate to benefit from Lou's deep experience gained over a successful career as a physician and founder and CEO of innovative public biotechnology companies, and I look forward to partnering with him in the leadership of our board."

Mr. Patterson has more than 25 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies.  Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics.  Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed, one of the world's largest healthcare dedicated investment firms.  Mr. Patterson currently serves as Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector.  He is a member of the Board of Directors for Homology Medicines, Inc., Modis Therapeutics, Inc., and Gilda's Club of New York City, which provides support for people living with cancer.  Mr. Patterson received his Bachelor's degree in Biochemistry from Bowdoin College.

Dr. Lange was the founder of CV Therapeutics, and as the Chairman, CEO, and Chief Scientific Officer, led the company through an IPO, the approval of two first-in-class cardiovascular drugs, RANEXA® and LEXISCAN®, and the sale of the company to Gilead Sciences, Inc.  Prior to joining industry, Dr. Lange spent 22 years in academic medicine at Harvard and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital and was one of the first academicians in molecular cardiology.  Dr. Lange is currently a General Partner at Asset Management Ventures, serves as a senior advisor to Gilead Sciences, Inc., and has served on numerous other public and private boards in both the non-profit and for-profit sectors.  Dr. Lange holds a Doctorate degree in Biochemistry from Harvard University and a Medical Doctor degree from Harvard Medical School.  He earned a Bachelor's degree from the University of Rochester.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases.  We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome.  We have two additional product candidates in development, including AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: anticipated clinical milestones, potential pipeline expansion, the timing and nature of clinical development and regulatory activities.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, establish and scale-up manufacturing processes that comply with regulatory requirements, protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
[email protected] 

Media Contact:
Katie Hogan
415.951.3398
[email protected]

SOURCE Audentes Therapeutics, Inc.

Related Links

http://audentestx.com